1. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti–multiple myeloma (MM) activity and overcome bortezomib resistance
   Dharminder Chauhan et al, 2004, Blood CrossRef
2. Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)
   Roy S. Herbst et al, 2004, Clinical Cancer Research CrossRef
3. Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides
   Sanjeev Shangary et al, 2004, Molecular Cancer Therapeutics CrossRef
4. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
   Jérôme Moreaux et al, 2004, Blood CrossRef
5. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
   Niels W. C. J. van de Donk et al, 2003, Blood CrossRef
6. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance
   Dharminder Chauhan et al, 2003, Blood CrossRef
7. Dexamethasone Inhibits Spheroid Formation of Thyroid Cancer Cells Exposed to Simulated Microgravity
   null Melnik et al, 2020, Cells CrossRef
8. Multiple myeloma with t(11;14): impact of novel agents on outcome
   Borja Puertas et al, 2023, Blood Cancer Journal CrossRef
9. Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
   Ying Chen et al, 2020, Frontiers in Oncology CrossRef
10. Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients
    Ashraf Z. Badros et al, 2005, Journal of Clinical Oncology CrossRef
11. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
    Dharminder Chauhan et al, 2007, Blood CrossRef
12. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
    Nur Najmi Mohamad Anuar et al, 2020, Frontiers in Pharmacology CrossRef